摘要
对哌拉西林和阿米卡星联用以头孢他啶为对照治疗４３例重度院内铜绿假单胞菌肺炎的疗效、细菌清除、不良反应等方面进行了评价，结果表明：两药联用组（２１例）总有效率为７１．４％，细菌清除率为８２．４％，不良反应发生率为９．５％；与头孢他啶组（２２例）比较无显著性差异（Ｐ＞０．０５）。结果揭示：对肝、肾功能正常重度院内铜绿假单胞菌肺炎患者，哌拉西林和阿米卡星联用可作为临床重要治疗方案之一予以选用。
Clinical efficacy of piperacillin combined with amikacin (P+A) versus ceftazidime in treatment of 43 patients with severe nosocomial pneumonia infected by Pseudomonas aeruginosa is accessed in this paper. It is demonstrated in the P+A group that percent of total efficacy is 71.40%, percent of isolates cleared is 82.4%, percent of adverse reaction is 9.5%, and no significant difference to the ceftazidime group.
出处
《中国抗生素杂志》
CAS
CSCD
北大核心
1996年第3期203-204,共2页
Chinese Journal of Antibiotics
关键词
肺炎
铜绿假单胞菌
药物疗法
哌拉西林
阿米卡星
Piperacillin combined with amikacin, Ceftazidime,Nosocomial pneumonia by Pseudomonas aeruginosa, Aapche Ⅱ
